GSK plc vs Marriott International Inc — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Marriott International Inc trades at $355.62 (market cap $91.14B). The key difference: GSK plc and Marriott International Inc are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | MAR | |
|---|---|---|
Market Cap | $102.60B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $402.54 |
52-Week Low | $38.22 | $259.04 |
Enterprise Value | $123.04B | $108.45B |
Dividend Yield | 3.57% | 0.84% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Marriott International (MAR) trades at $356.31, up 2.26% today, with a bearish technical signal from moving averages. Recent Q2 2026 earnings beat estimates with EPS of $3.19 versus $3.08 expected, driven by strong fee revenue growth. The company raised its 2026 outlook, supported by a record pipeline and AI-powered booking tools, though valuation remains elevated with a P/E of 36.18.
Outlook is mixed: analyst consensus targets $387.31 (8.7% upside) with 44% buy ratings, but high debt and Middle East weakness pose risks. The stock offers growth via fee-based model and dividends, but requires monitoring of RevPAR trends and macroeconomic pressures for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →